Noxopharm Limited 4 Let me begin by acknowledging Noxopharm founder Dr Graham Kelly, who stepped down as CEO in early 2022 after being involved since the conception of the company in 2015. Graham continues his involvement at Board level as a Non-Executive Director, and was instrumental in our choice of his successor. Graham’s departure from the executive team meant that we welcomed Dr Gisela Mautner into the CEO position after serving as our Chief Medical Officer for three years. Dr Mautner has vast international experience working in leadership roles for a number of the world’s largest pharmaceutical companies. Her experience and successful track record in launching new drugs, as well as a deep understanding of the complexities of scientific research and clinical trials, puts the company in a good stead as we execute and complete our current DARRT-2, CEP-2 and IONIC trials. Gisela has an extremely strong management team supporting her, all of whom have extensive experience and expertise in their respective fields. I am very confident our team headed by Dr Mautner will deliver great value creation for our shareholders. One of the key aspects of our refreshed science-driven strategy is building a pipeline of opportunities around Chairman’s Letter A year of progress and change Dear fellow Shareholders,
RkJQdWJsaXNoZXIy MjE2NDg3